Mineralocorticoid Receptor Blockade Improves Coronary Microvascular Function in Individuals With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Reduced coronary flow reserve (CFR), an indicator of coronary microvascular dysfunction, is seen in type 2 diabetes mellitus (T2DM) and predicts cardiac mortality. Since aldosterone plays a key role in vascular injury, the aim of this study was to determine whether mineralocorticoid receptor (MR) blockade improves CFR in individuals with T2DM. Sixty-four men and women with well-controlled diabetes on chronic ACE inhibition (enalapril 20 mg/day) were randomized to add-on therapy of spironolactone 25 mg, hydrochlorothiazide (HCTZ) 12.5 mg, or placebo for 6 months. CFR was assessed by cardiac positron emission tomography at baseline and at the end of treatment. There were significant and similar decreases in systolic blood pressure with spironolactone and HCTZ but not with placebo. CFR improved with treatment in the spironolactone group as compared with the HCTZ group and with the combined HCTZ and placebo groups. The increase in CFR with spironolactone remained significant after controlling for baseline CFR, change in BMI, race, and statin use. Treatment with spironolactone improved coronary microvascular function, raising the possibility that MR blockade could have beneficial effects in preventing cardiovascular disease in patients with T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581 · cited 2×
“Thus, CFR is a good intermediate marker of CVD. Aldosterone plays a critical role in the pathophysiology of CVD.”
BackgroundViel, E. C., Benkirane, K., Javeshghani, D., Touyz, R. M., & Schiffrin, E. L. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00304.2008 · Cited by 116
Cited by
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity
Jia, G., Hill, M. A., & Sowers, J. R. (2018) · Circulation Research · doi:10.1161/circresaha.117.311586 · Cited by 1,807
Bairey Merz, C. N., Pepine, C. J., Walsh, M. N., Fleg, J. L., Camici, P. G., Chilian, W. M., Clayton, J. A., Cooper, L. S., Crea, F., Di Carli, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024534 · Cited by 748
Self-citationJaisser, F., & Farman, N. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011106 · Cited by 327
Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences
Stehouwer, C. D. A. (2018) · Diabetes · doi:10.2337/dbi17-0044 · Cited by 306
Packer, M., Lam, C. S. P., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1902 · Cited by 185
Diuretics for Hypertension: A Review and Update
Roush, G. C., & Sica, D. A. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw030 · Cited by 142
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.05.006 · Cited by 64
Feng, Y., Huang, R., Kavanagh, J., Li, L., Zeng, X., Li, Y., & Fu, P. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00321-5 · Cited by 53
Moving toward the ideal insulin for insulin pumps
Cengiz, E., Bode, B., Van Name, M., & Tamborlane, W. V. (2016) · Expert Review of Medical Devices · doi:10.1586/17434440.2016.1109442 · Cited by 38
Metadata
- Authors
- Garg, R., Rao, A. D., Baimas-George, M., Hurwitz, S., Foster, C., Shah, R. V., Jerosch-Herold, M., Kwong, R. Y., Di Carli, M. F., & Adler, G. K.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-08-14
- Volume
- 64
- Issue
- 1
- Pages
- 236-242
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2152397139
- Cited by
- 133
- References
- 2
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.